Arcellx: Clinical stage development of Antigen Receptor Complex T-cells (ARC-T) that are readily silenced, activated and reprogrammed in vivo by administration of a tumo-targeting antigen protean called a sparX. The platform aims to achieve enhanced safety, improved efficacy, streamlined manufacturing and expanded utility. Backed by NEA, Novo, SR One, Takeda, Solasta, Quan, Clough, Mirae, JVC and LG. 
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - South Atlantic
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Immuno-Oncology, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Private
Market Cap
Private
Therapeutic Modalities
Cell Therapy
Website:
Address:
25 West Watkins Mill Road
Suite A
Gaithersburg, MD 20878
United States

Company Participants at Private Company Showcase NYC 2019

  • Angela Shen, Chief Medical Officer
  • David Hilbert, PhD, President and CEO
  • Han Lee, Chief Business Officer/Head of Finance, Business Development

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.